DE69033915D1 - Xanthinderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Anwendung - Google Patents
Xanthinderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische AnwendungInfo
- Publication number
- DE69033915D1 DE69033915D1 DE69033915T DE69033915T DE69033915D1 DE 69033915 D1 DE69033915 D1 DE 69033915D1 DE 69033915 T DE69033915 T DE 69033915T DE 69033915 T DE69033915 T DE 69033915T DE 69033915 D1 DE69033915 D1 DE 69033915D1
- Authority
- DE
- Germany
- Prior art keywords
- formula
- disorders
- processes
- preparation
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898906792A GB8906792D0 (en) | 1989-03-23 | 1989-03-23 | Treatment and compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69033915D1 true DE69033915D1 (de) | 2002-03-28 |
DE69033915T2 DE69033915T2 (de) | 2002-10-10 |
Family
ID=10653940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69033915T Expired - Fee Related DE69033915T2 (de) | 1989-03-23 | 1990-03-22 | Xanthinderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Anwendung |
Country Status (27)
Country | Link |
---|---|
US (4) | US5734051A (de) |
EP (2) | EP0389282B1 (de) |
JP (1) | JP2510889B2 (de) |
KR (1) | KR0160768B1 (de) |
CN (1) | CN1031641C (de) |
AT (1) | ATE213498T1 (de) |
AU (1) | AU629315B2 (de) |
CA (1) | CA2012686C (de) |
CZ (1) | CZ391891A3 (de) |
DE (1) | DE69033915T2 (de) |
DK (1) | DK0389282T3 (de) |
ES (1) | ES2173074T3 (de) |
FI (1) | FI95033C (de) |
GB (1) | GB8906792D0 (de) |
HK (1) | HK1040392A1 (de) |
HU (1) | HU207081B (de) |
IL (1) | IL93832A (de) |
MA (1) | MA21800A1 (de) |
MY (1) | MY109737A (de) |
NO (1) | NO175592C (de) |
NZ (1) | NZ233021A (de) |
PL (1) | PL164811B1 (de) |
PT (1) | PT93527B (de) |
SA (1) | SA90100215B1 (de) |
SK (1) | SK391891A3 (de) |
ZA (1) | ZA902170B (de) |
ZW (1) | ZW3690A1 (de) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5021422A (en) * | 1989-06-08 | 1991-06-04 | Senetek Plc | Method and composition for treating hyperproliferative skin diseases using 6-aminopurine cytokinins |
GB9020921D0 (en) * | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Novel compounds |
GB9020959D0 (en) * | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Novel compounds |
NZ240644A (en) * | 1990-11-21 | 1994-08-26 | Smithkline Beecham Corp | Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf) |
KR930703319A (ko) * | 1990-12-21 | 1993-11-29 | 데이빗 로버츠 | 키산틴 유도체 |
AU2229992A (en) | 1991-07-05 | 1993-02-11 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Use of substituted pyridazines against dermatosis |
AU3725893A (en) * | 1992-02-21 | 1993-09-13 | Smithkline Beecham Corporation | TNF inhibitors |
US5342841A (en) * | 1992-03-12 | 1994-08-30 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
CA2093403C (en) * | 1992-04-08 | 1999-08-10 | Fumio Suzuki | Therapeutic agent for parkinson's disease |
GB9210839D0 (en) * | 1992-05-21 | 1992-07-08 | Smithkline Beecham Plc | Novel compounds |
GB9215633D0 (en) * | 1992-07-23 | 1992-09-09 | Smithkline Beecham Plc | Novel treatment |
US6693105B1 (en) | 1992-11-16 | 2004-02-17 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
US6469017B1 (en) * | 1998-01-16 | 2002-10-22 | Cell Therapeutics, Inc. | Method of inhibiting interleukin-12 signaling |
GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
US6878715B1 (en) | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
US5646156A (en) * | 1994-04-25 | 1997-07-08 | Merck & Co., Inc. | Inhibition of eosinophil activation through A3 adenosine receptor antagonism |
US5591776A (en) | 1994-06-24 | 1997-01-07 | Euro-Celtique, S.A. | Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV |
US5922751A (en) | 1994-06-24 | 1999-07-13 | Euro-Celtique, S.A. | Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same |
ATE247655T1 (de) | 1994-12-13 | 2003-09-15 | Euro Celtique Sa | Dreifachsubstituierte thioxanthine |
DE69531506T2 (de) | 1994-12-13 | 2004-06-24 | Euroceltique S.A. | Arylthioxanthine |
EP0825993A1 (de) * | 1995-05-19 | 1998-03-04 | Chiroscience Limited | Xanthine und ihre therapeutische anwendung |
US6166041A (en) | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
US6075016A (en) | 1996-04-10 | 2000-06-13 | Euro-Celtique S.A. | 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity |
US5864037A (en) * | 1996-06-06 | 1999-01-26 | Euro-Celtique, S.A. | Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity |
US5958926A (en) * | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
GB9623859D0 (en) * | 1996-11-15 | 1997-01-08 | Chiroscience Ltd | Novel compounds |
GB9703044D0 (en) | 1997-02-14 | 1997-04-02 | Glaxo Group Ltd | Phenyl xanthine esters and amides |
ATE325610T1 (de) * | 1997-09-05 | 2006-06-15 | Kyowa Hakko Kogyo Kk | Xanthinderivative zur behandlung von hirnischämie |
MA24682A1 (fr) * | 1997-10-23 | 1999-07-01 | Smithkline Beecham Corp | Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant |
GB9817623D0 (en) | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
EP2193808A1 (de) | 1999-08-21 | 2010-06-09 | Nycomed GmbH | Synergistische Kombination |
WO2001068600A2 (en) * | 2000-03-16 | 2001-09-20 | Inflazyme Pharmaceuticals Limited | Benzylated pde4 inhibitors |
US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
US6586429B2 (en) * | 2000-11-29 | 2003-07-01 | Cell Therapeutics, Inc. | Tricyclic fused xanthine compounds and their uses |
EA007485B1 (ru) * | 2001-02-24 | 2006-10-27 | Берингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Производные ксантина, способ их получения, фармацевтическая композиция на их основе и способ ее получения |
EP1385523B1 (de) * | 2001-05-08 | 2008-08-06 | Blanchette Rockefeller Neurosciences Institute | Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen |
US6825180B2 (en) | 2001-05-18 | 2004-11-30 | Cell Therapeutics, Inc. | Pyridopyrimidine compounds and their uses |
WO2003015789A2 (en) * | 2001-08-15 | 2003-02-27 | Leo Pharma A/S | A pharmaceutical composition for dermal application |
ATE395349T1 (de) | 2001-08-28 | 2008-05-15 | Schering Corp | Polycyclische guanin phosphodiesterase inhibitoren |
US6943171B2 (en) | 2001-11-09 | 2005-09-13 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase V inhibitors |
US20030175314A1 (en) * | 2001-11-19 | 2003-09-18 | Didriksen Erik Johannes | Pharmaceutical composition for dermal application |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EA200501548A1 (ru) | 2003-04-01 | 2006-02-24 | Апплайд Резеч Системз Арс Холдинг Н.В. | Ингибиторы фосфодиэстераз при бесплодии |
CN1860119A (zh) * | 2003-07-31 | 2006-11-08 | 先灵公司 | 用于治疗勃起功能障碍的黄嘌呤磷酸二酯酶5抑制剂代谢物及其衍生物 |
EP1709966A4 (de) * | 2003-12-09 | 2009-04-29 | Prophylaktisches und/oder therapeutisches mittel für höhere gehirnfunktionsstörungen | |
US7713982B2 (en) | 2004-02-14 | 2010-05-11 | Smithkline Beecham Corporation | Xanthines with HM74A receptor activity |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
AR055369A1 (es) | 2005-08-10 | 2007-08-22 | Smithkline Beecham Corp | Compuestos derivados de xantina, su uso para preparar un medicamento para el tratamiento de una enfermedad mediada por el receptor hm74a, formulaciones y combinacion farmaceuticas que la comprenden y metodo de preparacion de los mismos |
WO2007109654A2 (en) * | 2006-03-21 | 2007-09-27 | Dr. Reddy's Laboratories Ltd. | Docetaxel polymorphs and processes |
EP1852108A1 (de) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Zusammensetzungen von DPP-IV-Inhibitoren |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
CA2810839A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine |
EP2057160A1 (de) | 2006-08-08 | 2009-05-13 | Boehringer Ingelheim International GmbH | Pyrrolo[3,2-d]pyrimidine als dpp-iv-inhibitoren zur behandlung von diabetes mellitus |
EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US8871751B2 (en) * | 2008-01-18 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
CN102149407A (zh) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | 治疗糖尿病和相关病症的组合疗法 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
BRPI0923121A2 (pt) | 2008-12-23 | 2015-08-11 | Boehringer Ingelheim Int | Formas salinas de compostos orgânico |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
CN107115530A (zh) | 2009-11-27 | 2017-09-01 | 勃林格殷格翰国际有限公司 | 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗 |
KR101927068B1 (ko) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
CN102971005A (zh) | 2010-06-24 | 2013-03-13 | 贝林格尔.英格海姆国际有限公司 | 糖尿病治疗 |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
WO2012118972A2 (en) | 2011-03-01 | 2012-09-07 | Synegy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
EP3517539B1 (de) | 2011-07-15 | 2022-12-14 | Boehringer Ingelheim International GmbH | Substituiertes dimeres chinazolinderivat, dessen herstellung und dessen verwendung in pharmazeutischen zusammensetzungen zur behandlung von diabetes typ i und ii |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2014131024A2 (en) | 2013-02-25 | 2014-08-28 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
EP2970384A1 (de) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonisten der guanylatcyclase und deren verwendungen |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
CN113388007A (zh) | 2013-06-05 | 2021-09-14 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
MX2016001714A (es) | 2013-08-09 | 2016-10-03 | Ardelyx Inc | Compuestos y metodos para inhibir el transporte de fosfato. |
JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害薬の医学的使用 |
SI3251675T1 (sl) | 2015-01-30 | 2021-08-31 | Shanton Pharma Pte. Ltd. | Preprečevanje ali zdravljenje sečnokislinske ali protinske bolezni |
AU2016246068B2 (en) | 2015-04-08 | 2020-08-27 | Lewis And Clark Pharmaceuticals, Inc. | Xanthine-substituted alkynyl carbamates/reverse carbamates as A2b antagonists |
EP3165224A1 (de) | 2015-11-09 | 2017-05-10 | Albert-Ludwigs-Universität Freiburg | Verwendung von pde4 hemmern zur prophylaxe und/oder therapie von dyslipoproteinaemie und verwandten erkrankungen |
WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
CA3022202A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
US20200368223A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Methods for inhibiting phosphate transport |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US757328A (en) * | 1903-02-07 | 1904-04-12 | Boehringer & Soehne | Art of preparing xanthin derivatives. |
US2517410A (en) * | 1947-08-15 | 1950-08-01 | Searle & Co | Hydroxy alkyl xanthines and the production thereof |
US2534813A (en) * | 1950-01-21 | 1950-12-19 | Searle & Co | 8-haloxanthine salts of cyclic-aminoalkyl benzohydryl ethers and the production thereof |
US4120947A (en) * | 1976-03-31 | 1978-10-17 | Cooper Laboratories, Inc. | Xanthine compounds and method of treating bronchospastic and allergic diseases |
CH654008A5 (fr) * | 1979-05-22 | 1986-01-31 | Nestle Sa | Procede de preparation de 1,3,7-trialkylxanthines. |
IT1200944B (it) * | 1982-08-10 | 1989-01-27 | Malesci Sas | Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico |
US4593095A (en) * | 1983-02-18 | 1986-06-03 | The Johns Hopkins University | Xanthine derivatives |
US4567183A (en) * | 1983-03-11 | 1986-01-28 | Analgesic Associates | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same |
US4558051A (en) * | 1983-10-11 | 1985-12-10 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same |
DE3406533A1 (de) * | 1984-02-23 | 1985-08-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten |
US4666914A (en) * | 1985-05-13 | 1987-05-19 | Schering Corporation | Anti-inflammatory and anti-allergic substituted-2,3-dihydro-6-(hydroxy)pyrimido[2,1-f]-purine-4,8(1H,9H)-diones |
GB8610136D0 (en) * | 1986-04-25 | 1986-05-29 | Wellcome Found | Compounds |
GB8621869D0 (en) * | 1986-09-11 | 1986-10-15 | Beecham Group Plc | Treatment |
KR890005052A (ko) | 1986-12-22 | 1989-05-11 | 기오르지오 스키니나 | 신규 피페리딘 유도체 |
IT1197516B (it) * | 1986-12-24 | 1988-11-30 | Abc Ist Biolog Chem Spa | Derivati teofillinmetilanici e teofillinmetilditianici procedimento per la loro preparazione e composizioni farmaceutiche che li comprendono |
-
1989
- 1989-03-23 GB GB898906792A patent/GB8906792D0/en active Pending
-
1990
- 1990-03-20 MA MA22044A patent/MA21800A1/fr unknown
- 1990-03-21 ZA ZA902170A patent/ZA902170B/xx unknown
- 1990-03-21 CA CA002012686A patent/CA2012686C/en not_active Expired - Fee Related
- 1990-03-21 NO NO901300A patent/NO175592C/no unknown
- 1990-03-21 AU AU52083/90A patent/AU629315B2/en not_active Ceased
- 1990-03-21 NZ NZ233021A patent/NZ233021A/en unknown
- 1990-03-21 PT PT93527A patent/PT93527B/pt not_active IP Right Cessation
- 1990-03-21 IL IL9383290A patent/IL93832A/en unknown
- 1990-03-22 EP EP90303093A patent/EP0389282B1/de not_active Expired - Lifetime
- 1990-03-22 DE DE69033915T patent/DE69033915T2/de not_active Expired - Fee Related
- 1990-03-22 ES ES90303093T patent/ES2173074T3/es not_active Expired - Lifetime
- 1990-03-22 HU HU901792A patent/HU207081B/hu not_active IP Right Cessation
- 1990-03-22 AT AT90303093T patent/ATE213498T1/de not_active IP Right Cessation
- 1990-03-22 ZW ZW36/90A patent/ZW3690A1/xx unknown
- 1990-03-22 KR KR1019900003902A patent/KR0160768B1/ko not_active IP Right Cessation
- 1990-03-22 EP EP00203905A patent/EP1120417A3/de not_active Withdrawn
- 1990-03-22 FI FI901447A patent/FI95033C/fi not_active IP Right Cessation
- 1990-03-22 DK DK90303093T patent/DK0389282T3/da active
- 1990-03-23 MY MYPI90000465A patent/MY109737A/en unknown
- 1990-03-23 JP JP2075359A patent/JP2510889B2/ja not_active Expired - Fee Related
- 1990-03-23 PL PL90284429A patent/PL164811B1/pl not_active IP Right Cessation
- 1990-03-23 CN CN90102240A patent/CN1031641C/zh not_active Expired - Fee Related
- 1990-05-08 SA SA90100215A patent/SA90100215B1/ar unknown
-
1991
- 1991-12-19 CZ CS913918A patent/CZ391891A3/cs unknown
- 1991-12-19 SK SK3918-91A patent/SK391891A3/sk unknown
-
1995
- 1995-06-07 US US08/477,157 patent/US5734051A/en not_active Expired - Fee Related
- 1995-06-07 US US08/474,093 patent/US5981535A/en not_active Expired - Fee Related
-
1998
- 1998-02-17 US US09/024,252 patent/US6180791B1/en not_active Expired - Fee Related
- 1998-12-15 HK HK02100617.1A patent/HK1040392A1/zh unknown
-
2000
- 2000-11-08 US US09/708,338 patent/US6531600B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69033915D1 (de) | Xanthinderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Anwendung | |
ATE79376T1 (de) | Dithioacetal-verbindungen, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
FR2695387B1 (fr) | Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. | |
DE3660286D1 (en) | Arylcyclobutylalkyl amines and their use as antidepressive medicines | |
DE68918406T2 (de) | Xanthinderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate. | |
DE3882438T2 (de) | Alkansulfonanilid-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung. | |
ATE48994T1 (de) | Benzimidazol-derivat, verfahren zu seiner herstellung und pharmazeutische zusammensetzung. | |
ATE86993T1 (de) | Heterotetracyclische laktamderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, die sie enthalten. | |
DE69129790D1 (de) | 5-Amino-5,6,7,8-Tetrahydrochinoline und verwandte Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
DE69024154T2 (de) | Pyrimidoindolderivate und Verfahren zu ihrer Herstellung | |
FR2655042B1 (fr) | Nouvelles benzothiazolinones substituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |